ConductScience.org, home

Paper36110930

Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.

Nota SPFT and 6 others. Front Oncol, 2022. Cited by 7 papers, by iCite.

Cite this record

ConductScience Library. Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy. Papers, record 36110930. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/36110930

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Chondroitin sulfate proteoglycan 4 expression in chondrosarcoma: A potential target for antibody-based immunotherapy.
PubMed
Journal
Front Oncol
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
7
iCite
Relative citation ratio, by iCite
0.55
iCite
Revised in PubMed
2022-09-17
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Nota SPFTSjoerd P F T
2Osei-Hwedieh DODavid O
3Drum DLDavid L
4Wang XXinhui
5Sabbatino FFrancesco
6Ferrone SSoldano
7Schwab JHJoseph H

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
134707200GD2 CAR T cells against human glioblastoma.NPJ Precis Oncol2021https://conductscience.org/library/papers/34707200PubMed
235110735Decade-long leukaemia remissions with persistence of CD4+ CAR T cells.Nature2022https://conductscience.org/library/papers/35110735PubMed
333494834CAR T cells in solid tumors: challenges and opportunities.Stem Cell Res Ther2021https://conductscience.org/library/papers/33494834PubMed
420852124CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer.J Natl Cancer Inst2010https://conductscience.org/library/papers/20852124PubMed
520455858CSPG4 in cancer: multiple roles.Curr Mol Med2010https://conductscience.org/library/papers/20455858PubMed
616181333Mechanisms of MHC class I-restricted antigen processing and cross-presentation.Immunol Rev2005https://conductscience.org/library/papers/16181333PubMed
725197555Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.J Immunother Cancer2014https://conductscience.org/library/papers/25197555PubMed
819738072Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition.Cancer Res2009https://conductscience.org/library/papers/19738072PubMed
933824268CAR-T cell therapy: current limitations and potential strategies.Blood Cancer J2021https://conductscience.org/library/papers/33824268PubMed
1030135176Tumor Antigen Escape from CAR T-cell Therapy.Cancer Discov2018https://conductscience.org/library/papers/30135176PubMed
1128420036Dedifferentiated chondrosarcoma: A survival analysis of 159 cases from the SEER database (2001-2011).J Surg Oncol2017https://conductscience.org/library/papers/28420036PubMed
1222004131CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.Pigment Cell Melanoma Res2011https://conductscience.org/library/papers/22004131PubMed
1322991614Histopathologic Differentiation between Enchondroma and Well-differentiated Chondrosarcoma: Evaluating the Efficacy of Diagnostic Histologic Structures.J Dent Res Dent Clin Dent Prospects2011https://conductscience.org/library/papers/22991614PubMed
1410199270Chondrosarcoma of bone: an assessment of outcome.J Bone Joint Surg Am1999https://conductscience.org/library/papers/10199270PubMed
1518469852The progenitor cell marker NG2/MPG promotes chemoresistance by activation of integrin-dependent PI3K/Akt signaling.Oncogene2008https://conductscience.org/library/papers/18469852PubMed
168077056The chondroitin sulfate proteoglycan NG2 is a tumour-specific antigen on the chemically induced rat chondrosarcoma HSN.Int J Cancer1994https://conductscience.org/library/papers/8077056PubMed
1716765318Intrinsic radiation resistance in human chondrosarcoma cells.Biochem Biophys Res Commun2006https://conductscience.org/library/papers/16765318PubMed
1833912442High TIL, HLA, and Immune Checkpoint Expression in Conventional High-Grade and Dedifferentiated Chondrosarcoma and Poor Clinical Course of the Disease.Front Oncol2021https://conductscience.org/library/papers/33912442PubMed
1911953591Treatment and outcome of recurrent pelvic chondrosarcoma.Clin Orthop Relat Res2002https://conductscience.org/library/papers/11953591PubMed
2029567707CAR T cell immunotherapy for human cancer.Science2018https://conductscience.org/library/papers/29567707PubMed

See all 42 referencesDownload CSV of references

Cited by8

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 7 citations.

PMIDTitleJournalYearIn PapersSource
42898659Application of CAR-T cell therapy in orthopedics: From bone malignancies to non-malignant musculoskeletal disorders.J Orthop Translat2026https://conductscience.org/library/papers/42898659PubMed
40969762Breaking barriers: enhancing CAR-armored T cell therapy for solid tumors through microenvironment remodeling.Front Immunol2025https://conductscience.org/library/papers/40969762PubMed
40867318Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision Medicine.Cancers (Basel)2025https://conductscience.org/library/papers/40867318PubMed
40004005Chondrosarcoma: New Molecular Insights, Challenges in Near-Patient Preclinical Modeling, and Therapeutic Approaches.Int J Mol Sci2025https://conductscience.org/library/papers/40004005PubMed
39018437Chondroitin sulfate proteoglycan 4 increases invasion of recessive dystrophic epidermolysis bullosa-associated cutaneous squamous cell carcinoma by modifying transforming growth factor-β signalling.Br J Dermatol2024https://conductscience.org/library/papers/39018437PubMed
38891109Emerging Treatments Targeting the Tumor Microenvironment for Advanced Chondrosarcoma.Cells2024https://conductscience.org/library/papers/38891109PubMed
38735753Chondroitin sulfate proteoglycan 4: An attractive target for antibody-based immunotherapy.Proc Jpn Acad Ser B Phys Biol Sci2024https://conductscience.org/library/papers/38735753PubMed
37745839Role of immunotherapy in chondrosarcoma: A case report and review of the literature.Ther Adv Med Oncol2023https://conductscience.org/library/papers/37745839PubMed

Download CSV of cited by

Genes12

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/36110930

GET https://conductscience.org/api/papers/v1/36110930/references?page=2